SUSPENDED

Testing RG1-VLP Vaccine to Prevent HPV-related Cancers

Talk to us

Conditions

Human Papillomavirus-Related Carcinoma

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This phase I trial tests the safety, side effects, and best dose of RG1-virus-like particle (VLP) in preventing human papillomavirus (HPV)-related cancers in women. RG1-VLP is a vaccine that aims to protect against rare HPV types not targeted by currently approved HPV vaccines. HPV is a common sexually-transmitted infection that can cause certain genital and oral cancers. RG1-VLP contains a protein of HPV type 16 (HPV16) with a slightly different structure than the licensed Gardasil-9 vaccine. Gardasil-9 is approved by the Federal Drug Administration to help protect against diseases caused by some types of HPV. Gardasil-9 also contains 9 different HPV proteins. Both vaccines contain alum to stimulate the immune system. The usual approach for the prevention of HPV-related cancers for patients who are at increased risk is to consider the currently approved HPV vaccine like Gardasil-9, as well as to be followed closely by their doctor to watch for the development of cancer via routine pap smears. This trial may allow researchers to find out whether the RG1-VLP vaccine can safely trigger an immune response against HPV in healthy women and if it is better or worse than the usual approach for the prevention of HPV-related cancers.

Official Title

A Dose Escalation Phase I Trial of the Safety and Immunogenicity of RG1-VLP, A Candidate Broadly Protective Vaccine for the Prevention of HPV-Associated Cancer

Quick Facts

Study Start:2025-02-27
Study Completion:2027-06-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:SUSPENDED

Study ID

NCT05985681

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 60 Years
Sexes Eligible for Study:FEMALE
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Women, age 18 - 60 years. Because no dosing or adverse event (AE) data is currently available for the use of RG1-VLP in humans, children and adolescents are excluded from this study
  2. * White blood cell (WBC) between 3000/mm\^3 - institutional upper limit of normal
  3. * Hemoglobin (Hgb) between 10 g/dl - institutional upper limit of normal
  4. * Platelets \>= 100,000/mm\^3
  5. * Serum creatinine within institutional normal limits
  6. * Bilirubin =\< 2x institutional upper limit of normal
  7. * Alanine aminotransferase (ALT) =\< 2x institutional upper limit of normal
  8. * Aspartate aminotransferase (AST) =\< 2x institutional upper limit of normal
  9. * Human immunodeficiency virus (HIV)-1/HIV-2 negative
  10. * Hepatitis B and hepatitis C negative
  11. * The effects of RG1-VLP vaccination on the developing human fetus at the proposed doses are unknown. For this reason, all women of childbearing potential will have a pregnancy test and all heterosexually active women must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately
  12. * The following persons are not considered to be able to bear children and are therefore eligible to participate without the use of concurrent birth control:
  13. * Female with bilateral oophorectomy and/or hysterectomy
  14. * Female with fallopian tubes cut, tied or sealed
  15. * Female with sterilization implant (e.g. Adiana, Essure) placed \> 3 months prior to randomization
  16. * Female post-menopausal (\> 1 year since last menses or prior laboratory follicle stimulating hormone \[FSH\] value per institutional range indicating post-menopausal)
  17. * Eastern Cooperative Oncology Group (ECOG) performance status of =\< 1
  18. * Ability to understand and the willingness to sign a written informed consent document
  1. * History of any of the following:
  2. * Prior or current genital warts
  3. * Treatment for anogenital intraepithelial neoplasia (cervical intraepithelial neoplasia \[CIN\], anal intraepithelial neoplasia \[AIN\], vaginal intraepithelial neoplasia \[VAIN\], vulvar intraepithelial neoplasia \[VIN\])
  4. * Systemic cancer treatment within the prior year
  5. * History of anaphylaxis to vaccines
  6. * Any prior vaccination with Gardasil, Gardasil-9, or Cervarix or other HPV vaccine
  7. * Receipt of blood products within 3 months of enrollment, or continuing plasma donation
  8. * Participants receiving any other investigational agents
  9. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to the adjuvant or to RG1-VLP
  10. * Uncontrolled intercurrent illness or psychiatric illness/social situations that would limit compliance with study requirements or preclude protocol vaccination
  11. * Pregnant women or actively lactating women are excluded from this study because RG1-VLP is a vaccine with the potential for teratogenic or abortifacient effects
  12. * Planned receipt of any inactivated vaccine in the 2 weeks preceding and the 2 weeks following any trial vaccination
  13. * Planned receipt of any live attenuated vaccine in the 4 weeks preceding and the 4 weeks following any trial vaccination
  14. * Women with a history of bleeding disorders or use of anticoagulants (aspirin is acceptable)
  15. * Had prior medical diagnoses:
  16. * Rheumatoid arthritis or other auto-immune disease
  17. * Congenital or acquired immunodeficiency
  18. * Collagen vascular disease
  19. * Following medical treatments:
  20. * Current use of immunosuppressive drugs including corticosteroid use (inhaled or topical steroids are permitted)
  21. * Unrecovered major infections and/or surgical procedures

Contacts and Locations

Principal Investigator

Reinhard Kirnbauer
PRINCIPAL_INVESTIGATOR
Medical University of Vienna

Study Locations (Sites)

University of Wisconsin Carbone Cancer Center - University Hospital
Madison, Wisconsin, 53792
United States

Collaborators and Investigators

Sponsor: National Cancer Institute (NCI)

  • Reinhard Kirnbauer, PRINCIPAL_INVESTIGATOR, Medical University of Vienna

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-02-27
Study Completion Date2027-06-01

Study Record Updates

Study Start Date2025-02-27
Study Completion Date2027-06-01

Terms related to this study

Additional Relevant MeSH Terms

  • Human Papillomavirus-Related Carcinoma